Tofacitinib-d3 (citrate)

CAT: 0804-HY-40354ASSize: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-40354ASSize:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Tofacitinib-d3 (citrate) is deuterium labeled Tofacitinib (citrate) . Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.
CAS Number
[2701680-77-3]
Product Name Alternative
Tasocitinib-d3 (citrate) ; CP-690550-d3 (citrate)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Bacterial; Fungal; Influenza Virus; Isotope-Labeled Compounds; JAK
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection; Inflammation/Immunology
Purity
99.59
Solubility
10 mM in DMSO|DMSO : 28.57mg/mL (ultrasonic) |H2O : 3.33mg/mL (ultrasonic)
Smiles
O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C([2H])([2H])[2H])[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
Molecular Formula
C22H25D3N6O8
Molecular Weight
507.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Jiang JK, et al. Examining the chirality, conformation and selective kinase inhibition of 3- ((3R,4R) -4-methyl-3- (methyl (7H-pyrrolo[2,3-d]pyrimidin-4-yl) amino) piperidin-1-yl) -3-oxopropanenitrile (CP-690,550) . J Med Chem. 2008 Dec 25;51 (24) :8012-8.|[3]LaBranche TP, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012 Nov;64 (11) :3531-42.|[4]Onda M, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014 Jul 1;193 (1) :48-55.|[5]Yagi K, et al. Pharmacological inhibition of JAK3 enhances the antitumor activity of STI571 in human chronic myeloid leukemia. Eur J Pharmacol. 2018 Apr 15;825:28-33.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-40354A-01Tofacitinib (citrate)
HY-40354S5Tofacitinib-d3
HY-40354AR-01Tofacitinib (citrate) (Standard)
HY-40354S2Tofacitinib-13C, d3
HY-B0369AS-01Orphenadrine-d3 (citrate)
HY-W010981S-01Acetyl tributyl citrate-d3
HY-170013SN-Pyrrolidino Metonitazene-d3 (citrate)
HY-40354-01Tofacitinib
HY-40354STofacitinib-13C3
HY-40354S3Tofacitinib-13C

Alternative Products

CatalogName
RM-T060442-01Tofacitinib-D3 Citrate
RM-T060300-01Tofacitinib Citrate
bs-75613C-01Tofacitinib . citrate
467697-01Tofacitinib Citrate Impurity
290636-01Tofacitinib Citrate (CP-690550 Citrate)
MBS6025278-01CP-690550 Citrate (Tofacitinib Citrate)
MBS384554-01CP-690550 (Tofacitinib citrate)
MBS577420Tofacitinib (CP-690550) Citrate
A10241-500CP-690550 (Tofacitinib citrate) 500mg

Popular Products